We now have Quarter 4 H1B visa FY 2023 data and Quarter 4 PERM visa FY 2023 data and Quarter 4 H2A visa FY 2023 data.
Employer Search tool is moved to it's own page: "H1B Visa Data Search Tool"

Statistics and Summary

Kate C Robins has been assisting clients through the H1B Visa process since 2020.

As of 2022, Kate C Robins has succesfully submitted and recieved certification for 255 cases.

Kate C Robins is located in Boston, MA, and has represented 10 employers for the H1B Visa Process

260
Cases Handled
255
Cases Certified
98.08%
Approval

Cases Handled by Kate C Robins

Case Number Case Status Job Title Industry Name Employer Name Year
I-200-22034-875144 Certified Bioinformatics Scientists Scientific Research And Development Services Intellia Therapeutics 2022
I-200-21336-740062 Certified Bioinformatics Scientists Scientific Research And Development Services Intellia Therapeutics 2022
I-200-20282-873806 Certified Bioinformatics Scientists Biological Product Except Diagnostic Manufacturing Biogen Inc 2021
I-200-23067-833093 Certified Biochemists And Biophysicists Research And Development In Biotechnology Except Nanobiotechnology Intellia Therapeutics 2023
I-200-23067-833068 Certified Biochemists And Biophysicists Research And Development In Biotechnology Except Nanobiotechnology Intellia Therapeutics 2023
I-200-23067-833055 Certified Biochemists And Biophysicists Research And Development In Biotechnology Except Nanobiotechnology Intellia Therapeutics 2023
I-200-22146-214381 Certified Biochemists And Biophysicists Research And Development In Biotechnology Except Nanobiotechnology Intellia Therapeutics 2022
I-200-22139-191942 Certified Biochemists And Biophysicists Research And Development In Biotechnology Except Nanobiotechnology Intellia Theapeutics 2022
I-200-21294-660944 Certified Biochemists And Biophysicists Research And Development In Biotechnology Except Nanobiotechnology Intellia Therapeutics Inc 2022
I-200-22110-087228 Certified Biochemists And Biophysicists Scientific Research And Development Services Intellia Therapeutics 2022